- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02252666
Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The intervention will be similar to that used in the investigators previous work with movement disorders, and will be tailored to the address issues unique to individuals with advanced MS.
The study will enroll a total of 6 subjects having advanced MS that present with significant seated and standing balance, posture, or movement control deficits due to MS.
Subjects will complete twice-daily lab training for two weeks (5 days/week). Each lab training (morning and afternoon) includes 1.5 to 2 hours of instruction in balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training.
Activities are performed in 20-minute sessions with concomitant electrical stimulation of the tongue. The intervention is customized according to each subject's particular symptoms and tolerance. If a subject is not able to perform this amount of training, the training will be adapted to a level that is tolerable.
After these 2 weeks, subjects will continue to perform these same intervention activities at home for 4 weeks. They will return to the lab for 1 week of training and testing, then perform home training for 4 weeks. This cycle is repeated for a total of 5 cycles.
After the 6 months have been completed, subjects may choose to participate in an optional second phase of the study. The second phase includes an additional 12 months of participation in which subjects perform the intervention activities at home training and return to the lab on time per month for 2 hours of testing and 2 hours of training.
If successful, this study would indicate that CN-NINM intervention may reduce the symptoms of advanced MS.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53711
- TCNL, 455 Science Drive, Suite 165
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must be age 18 or older.
Subjects will have a score between 6.5 to 7.5 on the Kurtzke Expanded Disability Status Scale (EDSS). The EDSS is a method of quantifying disability in people with multiple sclerosis.
- Score of 6.5: needs constant bilateral support to walk 20 meters without resting.
- Score of 7.0: unable to walk beyond five meters even with aid, and is essentially restricted to a wheelchair; wheels self and transfers alone, and is active in wheelchair about 12 hours a day.
- Score of 7.5: unable to take more than a few steps and is restricted to wheelchair, and may need aid to transfer; wheels self, but may require a motorized chair for a full day's activities.
Subjects will have reached a plateau in an MS focused physical rehabilitation program in the 6 months prior to enrollment.
- Requiring prior physical therapy will ensure that subjects have a core level of function that will allow them to participate in the study.
- Requiring that subjects have reached a plateau will ensure that subjects' response to the intervention is due to the use of the device and not to the physical exercises alone.
- Subjects who have participated in a physical rehabilitation program demonstrate that they are willing and able to commit to a rigorous training regimen.
- Subjects will have a maximum score of 20 on the Trunk Impairment Scale (TIS). The TIS assesses static dynamic sitting balance and trunk coordination in a sitting position. A score of 20 or lower indicates that their ability to adequately maintain sitting posture is affected.
- Subjects may have upper extremity involvement.
- Subjects may have additional symptoms of nystagmus, dysarthria, sensory disturbance, pain, and/or bowel and bladder function. As they present, we will use appropriate assessments at baseline and successive study test points.
- Subjects are their own legal guardians, and are able to understand and give informed consent.
Exclusion Criteria:
Subjects will have no major co-morbidities, especially neurological disorders, uncontrolled pain, hypertension or diabetes. All subjects, if on medications, will not have had any major changes in type or dosage in within 3 months of enrollment. Additionally, candidates will be excluded if they:
- have Functional Systems Scores (FSS) 4 or greater for pyramidal, cerebellar, brainstem, and sensory functions; 3 or greater for bowel and bladder function; and 2 or greater for cerebral function;
- are able to walk independently;
- use tobacco products (these activities tend to reduce tactile sensitivity in the oral cavity);
- have any oral abrasions, cuts, cold sores, piercings, tissue inflammation, or have had oral surgery within the previous 3 months;
- have a pacemaker, or are identified as at-risk for cardiovascular events;
- have a history of seizures;
- have a communicable disease;
- have a biomechanical prosthetic;
- are females who are pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neuromodulation Rehabilitation
Balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training using neurostimulation modulation.
2-week in lab intervention training, training at home and periodic return for follow-up testing and instruction on the next phase of the intervention.
|
CN-NINM uses sequenced patterns of electrical stimulation on the tongue.
Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Trunk Impairment Scale (TIS)
Time Frame: Change from Baseline at 2, 6, 11, 16, and 21 weeks
|
Static and dynamic sitting balance and trunk coordination are evaluated by a clinician.
It is scored on a scale from 0-23, where the higher the score, the more improved the balance.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, and 21 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Static Standing Balance Test
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Clinician measures standing balance for up to 30 seconds in each of 5 conditions: feet 10 cm apart, feet together, stride stance, tandem stance, and single leg stance with eyes open and eyes closed.
Total score is the sum of all 5 conditions.
Higher scores indicate better balance.
Performance-based and tested in participants who possessed the ability to perform the assessment.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Impact of Visual Impairment Scale (IVIS)
Time Frame: Change from Baseline at 2, 6, 11, 16, and 21 weeks
|
A 5-item self-report questionnaire that assesses the extent to which various activities dependent upon vision are affected by MS-related visual problems.
Scores range from 0-15, with higher scores indicating a greater impact of visual problems on daily activities.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, and 21 weeks
|
Medical Outcomes Study (MOS) Pain Effects Scale (PES)
Time Frame: Change from Baseline at 2, 6, 11, 16, and 21 weeks
|
A self-report scale that assesses the ways in which pain and unpleasant sensation interfere with mood, ability to walk or move, sleep, work, recreation, and enjoyment of life.
This assessment is used for subjects who have pain.
Scores can range from 6-30.
Items are scaled so that higher scores indicate a greater impact of pain on a patient's mood and behavior.
Symptom specific test, only used for participants who presented symptom.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, and 21 weeks
|
Bladder Control Scale (BLCS)
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
A 4-item self-report scale to evaluate the impact of bladder control on lifestyle.
This assessment is used for subjects with bladder issues.
Scores can range from 0-22, with higher scores indicating greater bladder control problems.
Symptom specific test, only used for participants who presented symptom.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Bowel Control Scale (BWCS)
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
A 5-item self-report scale to evaluate the impact of bowel control on lifestyle.
This assessment is used for subjects with bowel issues.
Scores can range from 0-26, with higher scores indicating greater bowel control problems.
Symptom specific test, only used for participants who presented symptom.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
A brief, clinician-administered test that helps determine the neuropsychological status of adults who have neurologic injury or disease such as dementia, head injury, and stroke.
This tool consists of a battery of tests.
Raw scores are transformed to a 0-120 scale, with a higher score indicating higher function.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Walking Distance
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Clinician measures how far the individual can walk until fatigue requires him/her to stop.
Longer distances demonstrate improvement.
Performance-based and tested in participants who possessed the ability to perform the assessment.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Walking Speed
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Assessed by timing the first 25 feet that the person walked.
Performance-based and tested in participants who possessed the ability to perform the assessment.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
12-item MS Walking Scale (MSWS-12)
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
A 12-item self-report measure of the impact of MS on a person's walking.
Raw scores are transformed to a 0-100 scale.
A reduction in score indicates improvement.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Box & Blocks (B&B) Assessment - Right
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
A standardized clinical assessment of gross upper limb dexterity.
Subjects move small blocks from one side of a box to the other within a time period (one minute).
Each side is tested separately.
The score is the number of blocks moved from 0-150.
A higher score indicates improvement.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Box & Blocks (B&B) Assessment - Left
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
A standardized clinical assessment of gross upper limb dexterity.
Subjects move small blocks from one side of a box to the other within a time period (one minute).
Each side is tested separately.
The score is the number of blocks moved from 0-150.
A higher score indicates improvement.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Multiple Sclerosis Impact Scale (MSIS-29) - Physical
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
A 29-item self-report tool that measures the impact of MS on day-to-day life.
There are 3 scores, physical, psychological, and total score.
Raw scores are transformed to a 0-100 scale.
A higher score indicates a greater impact of disease on daily function.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Multiple Sclerosis Impact Scale (MSIS-29) - Psychological
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
A 29-item self-report tool that measures the impact of MS on day-to-day life.
There are 3 scores, physical, psychological, and total score.
Raw scores are transformed to a 0-100 scale.
A higher score indicates a greater impact of disease on daily function.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Modified Fatigue Impact Scale (MFIS)
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
A self-report tool that assesses the perceived impact of fatigue on daily activities.
Consists of 21 items selected from the Fatigue Impact Scale.
Scored on a 0-84 scale.
A higher score indicates a greater impact of fatigue on daily activities.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Gross Motor Function Measure (GMFM)
Time Frame: Change from Baseline at 6, 11, 16, 21 and 27 weeks
|
The GMFM a standardized observational instrument that measures change in gross motor function.
Subscales include lying & rolling; sitting; crawling & kneeling; standing; and walking, running & jumping.
For the complete test, the raw scores are converted to a 0-100 scale, with higher scores indicating greater functional mobility.
The items that we used were scored on a 0-3 scale and changes reported in percent improvement.
Performance-based and tested in participants who possessed the ability to perform the assessment.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 6, 11, 16, 21 and 27 weeks
|
Slump Test
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Measures and quantifies changes in trunk control during functional sitting.
It was quickly determined that this test duplicated the TIS and was difficult to score objectively so the decision was made not to use it for the study.
Performance-based and tested in participants who possessed the ability to perform the assessment.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Modified Rivermead Mobility Index
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
An 8 item assessment that quantifies the ability to perform transfers.
It has been validated in persons with stroke and a mixed neurologic population (43% MS).
Score is a 0-40 scale.
A higher score indicates higher function.
Performance-based and tested in participants who possessed the ability to perform the assessment.
Effect size is reported (quantified difference between baseline and time point).
The larger the absolute value, the stronger the effect.
Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Video Nystagmography (VNG)
Time Frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
VNG is a standardized eye tracking test used to measure static and dynamic eye movement control to detect oculomotor abnormalities typically associated with degenerative neurological disorders, particularly in the brainstem and cerebellum.
The subject wears goggles while an infrared video camera monitors and records eye movement as the eyes follow a dot on a computer screen.
|
Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mitchell E Tyler, MS, University of Wisconsin, Madison
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-1060
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Neuromodulation Rehabilitation
-
Seoul National University Bundang HospitalUnknownMalignant Female Reproductive System NeoplasmKorea, Republic of
-
University of ExtremaduraActive, not recruitingStroke/Brain AttackSpain
-
Noctrix Health, Inc.CompletedRestless Legs SyndromeUnited States
-
University of Las Palmas de Gran CanariaUniversity of Castilla-La ManchaCompleted
-
Aníbal Báez SuárezRecruiting
-
University of Las Palmas de Gran CanariaRecruiting
-
University of Las Palmas de Gran CanariaCompleted
-
University of Las Palmas de Gran CanariaRecruitingKnee ProsthesisSpain
-
Friedrich-Alexander-Universität Erlangen-NürnbergRecruitingAnorectal Malformations | Chronic Constipation With Overflow | Encopresis With Constipation and Overflow Incontinence | Hirschsprung's Disease | Sacral DysgenesisGermany
-
Noctrix Health, Inc.National Institute of Neurological Disorders and Stroke (NINDS)CompletedRestless Legs SyndromeUnited States